As of 2026-04-05, the Relative Valuation of Supernus Pharmaceuticals Inc (SUPN) is (10.49) USD. This relative valuation is based on P/E multiples. With the latest stock price at 50.48 USD, the upside of Supernus Pharmaceuticals Inc based on Relative Valuation is -120.8%.
The range of the Relative Valuation is (9.32) - (12.14) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 8.8x - 18.1x | 12.8x |
| Forward P/E multiples | 13.9x - 20.3x | 18.5x |
| Fair Price | (9.32) - (12.14) | (10.49) |
| Upside | -118.5% - -124.1% | -120.8% |
| Date | P/E |
| 2026-04-02 | -75.40 |
| 2026-04-01 | -76.83 |
| 2026-03-31 | -77.21 |
| 2026-03-30 | -73.71 |
| 2026-03-27 | -73.97 |
| 2026-03-26 | -75.87 |
| 2026-03-25 | -74.77 |
| 2026-03-24 | -73.76 |
| 2026-03-23 | -73.56 |
| 2026-03-20 | -71.34 |
| 2026-03-19 | -72.95 |
| 2026-03-18 | -73.62 |
| 2026-03-17 | -75.91 |
| 2026-03-16 | -75.00 |
| 2026-03-13 | -74.55 |
| 2026-03-12 | -75.37 |
| 2026-03-11 | -79.49 |
| 2026-03-10 | -80.16 |
| 2026-03-09 | -80.91 |
| 2026-03-06 | -80.46 |
| 2026-03-05 | -81.06 |
| 2026-03-04 | -83.02 |
| 2026-03-03 | -81.49 |
| 2026-03-02 | -82.28 |
| 2026-02-27 | -81.75 |
| 2026-02-26 | -83.27 |
| 2026-02-25 | -84.12 |
| 2026-02-24 | -79.61 |
| 2026-02-23 | -75.71 |
| 2026-02-20 | -75.97 |
| 2026-02-19 | -76.70 |
| 2026-02-18 | -74.98 |
| 2026-02-17 | -77.10 |
| 2026-02-13 | -75.94 |
| 2026-02-12 | -74.46 |
| 2026-02-11 | -76.68 |
| 2026-02-10 | -76.44 |
| 2026-02-09 | -76.62 |
| 2026-02-06 | -77.15 |
| 2026-02-05 | -73.74 |
| 2026-02-04 | -73.31 |
| 2026-02-03 | -72.29 |
| 2026-02-02 | -72.86 |
| 2026-01-30 | -71.93 |
| 2026-01-29 | -73.28 |
| 2026-01-28 | -73.10 |
| 2026-01-27 | -73.85 |
| 2026-01-26 | -73.43 |
| 2026-01-23 | -72.07 |
| 2026-01-22 | -73.34 |